Steiner, Israel <br/><br/>
Quantitative risk-benefit analysis of natalizumab.  [electronic resource] 

 -  Neurology  May 2009 
 - 1791-2; author reply 1791-2 p.  digital 
<br/><br/> Publication Type: Comment; Letter 
<br/><br/><label>ISSN: </label>1526-632X 
<br/><br/><label>Standard No.: </label>10.1212/01.wnl.0000347020.85704.36  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Clinical Trials as Topic<br/>Humans<br/>Leukoencephalopathy, Progressive Multifocal--etiology<br/>Multiple Sclerosis, Relapsing-Remitting--complications<br/>Natalizumab<br/>Risk Factors